Primary familial brain calcification (PFBC) is a neurological disease characterized by calcium phosphate deposits in the basal ganglia and other brain regions and has thus far been associated with SLC20A2, PDGFB or PDGFRB mutations. We identified in multiple families with PFBC mutations in XPR1, a gene encoding a retroviral receptor with phosphate export function. These mutations alter phosphate export, implicating XPR1 and phosphate homeostasis in PFBC.
VOLUME 47 | NUMBER 6 | JUNE 2015 Nature GeNetics b r i e f c o m m u n i c a t i o n s absent from variation databases, is predicted to be non-damaging. The p.Ile575Val variant has a minor allele frequency of 0.068% in ExAC, interchanges two hydrophobic residues in a transmembrane domain and is likely to represent a rare polymorphism. None of these variants were found in two in-house series (126 French and 161 North American controls of European ancestry screened with exome sequencing and targeted resequencing, respectively).
XPR1 is a cell surface multipass membrane protein initially identified as the mammalian receptor for xenotropic murine leukemia viruses (X-MLV) 9, 10 . It contains an N-terminal SPX domain ( Fig. 1a ) that is also found in several yeast and plant proteins involved in phosphate homeostasis 11, 12 . We have recently shown that XPR1 mediates phosphate export 13 , a function that is highly conserved across evolution 13, 14 . We tested all the newly identified XPR1 variants in a complementation assay for phosphate efflux in human cells 13 , wherein phosphate efflux decreased after the introduction of XPR1-targeting small interfering siRNA (siRNA) but was restored by the expression of wild-type or mutant XPR1 (Fig. 1b) . We found that Leu145Pro mutant XPR1 neither reestablished phosphate efflux nor served as the receptor for X-MLV during infection ( Fig. 1b and Supplementary  Table 4 ). Consistent with this observation, phosphate efflux was also impaired in the peripheral blood mononuclear cells (PBMCs) isolated from the two patients harboring the p.Leu145Pro alteration that we tested (Fig. 1e) . This substitution affected cell surface exposure of XPR1 on HEK293T cells, as monitored by flow cytometry with an XPR1 ligand (XRBD) derived from the X-MLV envelope glycoprotein 13 , although the expression levels of Leu145Pro XPR1 remained substantial ( Fig. 1c,d) . Remarkably, expression of Leu145Pro XPR1 specifically decreased the phosphate efflux of endogenous XPR1 ( Fig. 1b) , whereas we observed no effect on the expression of the phosphate importers PiT1 and PiT2 or on phosphate uptake ( Supplementary  Fig. 3) , supporting a trans dominant-negative effect of the Leu145Pro mutant on wild-type XPR1. In contrast, the four other mutants were present at the plasma membrane and served as potent retroviral receptors ( Supplementary Fig. 4 and Supplementary Table 4 ). The three variants p.Ser136Asn, p.Leu140Pro and p.Leu218Ser all affected XPR1 a c.434T>C transition in the mammalian XPR1 gene (NM_004736.3; encoding xenotropic and polytropic retrovirus receptor 1), predicted to result in a deleterious p.Leu145Pro alteration at a highly conserved residue within the SPX domain shared by SYG1/PHO81/XPR1 proteins 9 ( Fig. 1a) and absent from repositories of sequence variation, including the Exome Aggregation Consortium (ExAC) database.
Further sequencing of XPR1 in 86 additional sporadic and familial cases identified the same p.Leu145Pro variant in two affected individuals from a family of French descent and five additional missense variants. Pedigree analyses and the segregation patterns of variants surrounding XPR1 suggested that the two families carrying the p.Leu145Pro variant were not related (Online Methods). Three other variants, p.Ser136Asn, p.Leu140Pro and p.Leu218Ser (Fig. 1a, Table 1 , Supplementary Fig. 2 and Supplementary Table 3 ), all located in the SPX domain or in its vicinity and predicted to be damaging, were absent from variation repositories. The p.Lys53Arg variant, also Fig. 4 ). Expression of XPR1 with the predicted non-damaging p.Lys53Arg substitution restored phosphate efflux to wild-type levels, making the causative role of this variant in PFBC uncertain. After SLC20A2, XPR1 is the second PFBC-associated gene to encode a phosphate transporter. The presence of PFBC-causing mutations in SLC20A2 (PiT2) 2,3 suggests that inhibition of phosphate uptake may lead to deposition of calcium phosphate in the vascular extracellular matrix. In contrast, inhibition of phosphate export, associated with the XPR1 mutations, is expected to increase the intracellular phosphate concentration. Therefore, XPR1 mutation-mediated calcium phosphate precipitation is likely to occur intracellularly, as is characteristic of osteoblasts during bone mineralization 15 .
Phosphate import and export are interdependent functions that regulate intracellular phosphate homeostasis. However, it is not yet known whether XPR1 and PiT2 coregulate each other and/or are regulated by common factors. The PFBC-associated PDGFRB and PDGFB proteins, known to modulate phosphate transport, may also function as regulators of XPR1 and PiT2 levels in the brain 5, 6, 16 . PiT1 and PiT2 expression is modulated by the extracellular phosphate concentration 17 , and we have recently reported that high-phosphate medium increases phosphate export whereas starvation decreases it 13 . It is therefore possible that alterations of PiT2-mediated phosphate transport might also alter XPR1-dependent phosphate export in areas of the brain where phosphate transporters are expressed 18 .
Five of the six XPR1 variants described in this study are clustered in the cytoplasmic N-terminal portion of XPR1 (Fig. 1a) , and four lie in the SPX domain, which appears to be dispensable for intrinsic phosphate export activity 13 . A role of the SPX domain in protein trafficking may explain the retention of the Leu145Pro XPR1 mutant in cells. Interestingly, the corresponding substitution disrupts a dileucine motif known to be involved in protein endocytosis and plasma membrane trafficking 19 that is highly conserved across evolution ( Supplementary  Fig. 5 ). The other mutants with impaired phosphate efflux activity were efficiently localized to the plasma membrane, suggesting function(s) other than trafficking for the SPX domain. Notably, the SPX domain was shown to modulate intracellular cyclic AMP (cAMP) levels, presumably through interactions with G protein β subunits 20 , although its role in phosphate regulation remains to be elucidated.
XPR1 is actively expressed in neuronal stem cells 13 and human brain 10 , and Xpr1 is expressed in several regions of the mouse brain (Allen Mouse Brain Atlas database; see URLs). Direct involvement of XPR1 in phosphate export and its expression pattern in brain support its role in cerebral phosphate homeostasis. These results identify XPR1 as a new gene associated with PFBC and provide new insights into the role of phosphate homeostasis in PFBC etiology.
URLs. Allen Mouse Brain Atlas database, http://mouse.brain-map.org/; TOPO2 transmembrane protein display software, http://www.sacs.ucsf. edu/TOPO2/; dbSNP database, http://www.ncbi.nlm.nih.gov/SNP/; 1000 Genomes Project, http://www.1000genomes.org/; Exome Variant Server, http://evs.gs.washington.edu/EVS/; Exome Aggregation Consortium (ExAC), http://exac.broadinstitute.org/.
MeThods
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
oNLINe MeThods
Patients. Patient enrollment. Seventeen individuals from one family were enrolled in this study through the University of California Los Angeles (UCLA) Medical Center after providing informed consent. The clinical features of this family were described in a previous report 7 . An additional 86 cases self-defined as Caucasian with a clinical diagnosis of idiopathic brain calcification (either sporadic or with family history of brain calcifications) and with no mutations in SLC20A2, PDGFB and PDGFRB were recruited at collaborating institutions. Some of these individuals were included in previous clinical or genetic studies (47 of them were recruited using inclusion criteria as previously described 21 ). The study was approved by the UCLA Institutional Review Board. Patients gave informed, written consent for genetic analyses. Medical history was obtained and neurological examinations were performed for all probands and additional family members. Serum calcium and parathormone levels were assayed to exclude calcium dysregulation and other metabolic disorders that would cause brain calcifications unrelated to PFBC.
Neuroimaging. Head CT scans were performed as part of the diagnostic workup or were reviewed for the presence of calcifications or other brain abnormalities. Subjects with CT scans positive for calcifications were given an affected disease status, whereas patients with a negative CT scan who were >50 years of age and remained asymptomatic until their death were assigned an unaffected disease status. Subjects whose CT scans were negative but who were under the age of 50 years and subjects whose CT scan results were not available were classified as having unknown disease status.
Exome analysis. Genomic DNA was extracted from peripheral blood and fragmented by sonication, using the Covaris acoustic disruptor (E210, Covaris) to achieve an average fragment size of 200 bp. We used 1 µg of DNA from each individual for the construction of a paired-end library. Exome capture was performed using the TruSeq DNA Sample Prep kit (Illumina).
Sequencing was performed on an Illumina Genome Analyzer HiSeq 2500 according to the manufacturer's instructions. We obtained 46.4 million 100base, paired-end reads per sample on average, with a 20× average depth of coverage within the targeted exome. Raw image files were processed with Illumina CASAVA 1.8 software. The sequencing reads were aligned to the NCBI human reference genome (GRCh37/hg19) using the Burrows-Wheeler Aligner (BWA). Variant calling was performed using the Genome Analysis Toolkit (GATK, version 2.6.4), and Qiagen Ingenuity Variant Analysis software was used for variant annotation and filtering. Filtering was carried out by applying a series of steps ( Supplementary Fig. 1b) : low-quality variants were filtered out using the Illumina Qscore threshold of 20; in addition, variants present in dbSNP138 and with a minor allele frequency (MAF) higher than 1% in the 1000 Genomes Project (see URLs) and Exome Variant Server (see URLs) databases were filtered out; finally, we focused on predicted missense, frameshift, stop-gain or stop-loss, and splice-site variants. The potential effect of the variants on protein function was assessed by PolyPhen-2, SIFT and MutationTaster. PolyPhen-2 is a software tool that predicts damaging effects by combining an evaluation of the properties of the mutated amino acid and the conservation of the residue 22 . SIFT is a tool developed to predict the deleterious effect of an amino acid substitution on the basis of sequence homology analysis 23 . MutationTaster is a web-based application that integrates information from several analysis tools. Disease potential is evaluated on the basis of evolutionary conservation, splice-site changes, loss of protein features and changes that might affect the amount of mRNA 24 . Residue conservation was evaluated using Genomic Evolutionary Rate Profiling (GERP), an algorithm that identifies constrained elements in multiple-sequence alignments by quantifying substitution deficits 25 . GERP score can range from −12.3 to 6.17, with 6.17 corresponding to the most conserved elements. The protein schematic (Fig. 1a) was created using TOPO2 transmembrane protein display software (see URLs). Variant frequency was also checked in the ExAC database (accessed February 2015; see URLs), where XPR1 has a mean coverage of 65.2× (range: 41-206×) across 115,519.9 alleles on average. Sanger sequencing analysis. Sanger sequencing was initially performed to screen the genes already known to be associated with PFBC (SLC20A2, PDGFRB and PDGFB) and to validate the variants identified through exome sequencing. Genomic DNA extracted from blood was used as template for PCR reactions to amplify the coding regions of SLC20A2 (NM_001257180.1), PDGFB (NM_002608.2) and PDGFRB (NM_002609.3), as well as that of XPR1 (NM_004736.3).
Cosegregation analysis. The maximum LOD score (recombination rate = 0) was computed assuming an autosomal dominant pattern of inheritance and a penetrance of 100% at age 50 years (12 informative meioses fulfilling these criteria), according to the formula Z(θ) = log((1 − θ) n − r θ r /(1/2) n ), where n is the total number of births, r is the number of recombinant types and θ is the recombination rate.
Analysis of relatedness between the two families carrying the c.434T>C
XPR1 variant. We studied the genealogy of both families whose members included carriers of the c.434T>C (p.Leu145Pro) variant. We obtained data back to the 1750s in one branch of the French family (mother of the proband, known to be affected) and could not find any common ancestry with the North American family of Swedish descent. Furthermore, we compared exome sequencing data from all affected and unaffected individuals from the North American family in XPR1 and the surrounding genes on chromosome 1 and identified three variants (one downstream and two upstream of XPR1) that were present in the affected individual and absent in the unaffected individual: rs7536561 (529 kb from the XPR1 variant), rs79485039 (113 kb from the XPR1 variant) and rs3747958 (125 kb from the XPR1 variant). We sequenced these SNPs in the proband of the French family who also carried the c.434T>C (p.Leu145Pro) mutation and found reference sequences for all of them. This analysis supports the hypothesis that the mutation occurred on different haplotypes in the two families.
Cells. HEK293T (human embryonic kidney) and CHO hamster cells were cultured in DMEM supplemented with 10% FBS (Invitrogen) and non-essential amino acids in a 5% CO 2 incubator at 37 °C under humid atmosphere. For phosphate-free incubations, cells were grown in phosphate-free DMEM supplemented with 10% dialyzed FBS. Cells were obtained from the American Type Culture Collection. Cell lines in this study were free from mycoplasma contamination, as determined by monthly testing.
PBMCs were isolated from peripheral blood collected in the presence of heparin from both healthy donors and patients who had signed informed consent for research purposes. Blood samples were subjected to density gradient separation on Histopaque-1077 (1:1 ratio; Sigma-Aldrich) and centrifuged 24 h after blood collection. After centrifugation, the PBMC layer was collected and washed in DMEM before evaluation of phosphate efflux.
Plasmids and siRNAs. The mutations encoding p.Leu145Pro, p.Lys53Arg, p.Ser136Asn, p.Leu140Pro and p.Leu218Ser were generated by site-directed mutagenesis using recombinant PCR (details are available upon request). Sequences encoding HA-tagged versions of human XPR1 were introduced into both the pCHIX expression vector 26 and the pLXSN retroviral vector 27 . The siRNA sequences (Integrated DNA Technologies) targeting the 3′ UTR of human XPR1 were as follows: 5′-GGAUUUCAUGCCAUCCCAUTT-3′ and 5′-GCACUUCCACCAUGUAUUATT-3′. siRNA directed against the firefly luciferase gene was used as a control. HEK293T cells grown on six-well plates coated with poly(d-lysine) were transfected with 50 pmol of siRNA per well using the calcium phosphate method.
Phosphate flux in human cells. Phosphate uptake and efflux from HEK293T cell monolayers, transfected 2 d before assays, were measured as previously described 9 . Briefly, for uptake measurements, cells were incubated for npg 30 min at 37 °C in phosphate-free DMEM supplemented with 0.5 µCi/ml 33 P (NEZ080500UC, PerkinElmer). Cell lysates were then assayed for radioactivity by scintillation counting and for protein content by the BCA protein assay (Pierce). The percentage of phosphate uptake was calculated as the ratio of cellular 33 P to the total amount of supplemented 33 P. For the efflux measurements, cells were incubated for 20 min at 37 °C in phosphate-free DMEM supplemented with 0.5 µCi/ml 33 P, gently washed three times with phosphate-free medium and then incubated in DMEM for 30 min at 37 °C in 10 mM phosphate before collection of the supernatant. The amount of 33 P in the supernatants and cell lysates was measured by liquid scintillation. The percentage of phosphate efflux was calculated as the ratio of released 33 P to total cellular 33 P. Phosphate efflux in PBMCs was assayed as described above with 5 × 10 5 cells per assay.
Immunoblotting. Whole-cell extracts (15 µg) were separated by 12% SDS-PAGE under reducing conditions, transferred to PVDF membranes and probed with antibodies against HA (3F10, Roche Applied Science; 1:5,000 dilution) or β-actin (A5441, Sigma-Aldrich; 1:5,000 dilution). Proteins of interest were detected with horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rat antibodies (1:5,000 dilution; SouthernBiotech) and visualized with the Pierce ECL western blotting substrate (Thermo Scientific), according to the manufacturer's protocol.
Flow cytometry. Cell surface expression of phosphate transporters was monitored on HEK293T cells with soluble ligands derived from the RBD of different Env proteins. XRBD, koala retrovirus (KoRV) RBD (KoRBD) and amphotropic-MLV RBD (ARBD) were used to detect XPR1, PiT1 and PiT2, respectively 13, 28 . Binding assays were carried out as previously described 13 . Briefly, 5 × 10 5 cells were resuspended in 200 µl of PBA (PBS with 2% FBS and 0.1% sodium azide) containing the proper RBD, incubated for 30 min at 37 °C, washed twice with PBA and incubated for 20 min at 4 °C with Alexa Fluor 488-conjugated anti-mouse IgG1 antibodies (1:500 dilution; Invitrogen). Cells were immediately analyzed on a FACSCalibur instrument (Becton Dickinson), and data analysis was performed using FlowJo software.
Virus production. LAPSN viral vectors were produced from 2 × 10 6 HEK293T cells in 10-cm dishes cotransfected using the calcium phosphate method with an MLV-based LAPSN retroviral vector carrying the alkaline phosphatase reporter gene 29 (10 µg), the MLV Gag-Pol expression vector (pC57GPBEB; 5 µg) 30 , and expression vectors for either vesicular stomatitis virus glycoprotein (VSV-G) or the X-MLV envelope (Env) glycoprotein (5 µg). Virion-containing media were collected 2 d later, filtered through a 0.45-µm (pore size) filter and stored at −80 °C before use. LXSN viral vectors carrying wild-type or mutant XPR1 were produced under the same conditions, except that the LAPSN retroviral vector was replaced by the various XPR1 LXSN vectors. Viral infection and G418 selection. CHO cells stably expressing XPR1 constructs were generated by transducing CHO cells with the pL(XPR1)SN, pL(XPR1K53R)SN, pL(XPR1S136N)SN, pL(XPR1L140P)SN, pL(XPR1L145P)SN and pL(XPR1L218S)SN vectors or with empty pLXSN vector and selecting cells the next day with medium containing 1.5 mg/ml G418 (active fraction). G418-resistant clones were pooled after 2 weeks of selection before further experiments.
CHO cells (2 × 10 4 ) stably expressing wild-type XPR1 or the Lys53Arg, Ser136Asn, Leu140Pro, Leu145Pro or Leu218Ser mutants from the MLV-based LXSN retroviral vector were plated in 12-well plates and infected the following day with serial dilutions of replication-defective LAPSN retroviral vector pseudotyped with the X-MLV Env or VSV-G glycoprotein. Cells were stained 2 d later for alkaline phosphatase expression, as previously described 29 , and alkaline phosphatase-positive colonies were counted to determine viral titers (colony forming units (CFU)/ml).
Statistical analysis.
The Student's t test in GraphPad Prism 5 software was used to calculate P values, and the following convention was used: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
